Secondary infections after cytotoxic chemotherapy in patient with hematological malignancies

Basit Öğe Kaydı
dc.authoridKose, Adem/0000-0002-1853-1243
dc.authoridGozel, Mustafa Gokhan/0000-0001-5187-7388
dc.authoridBUYUKTUNA, SEYIT ALI/0000-0001-6518-7361
dc.authorwosidKose, Adem/AAD-1226-2020
dc.authorwosidGozel, Mustafa Gokhan/ABG-1439-2020
dc.contributor.authorBuyuktuna, Seyit Ali
dc.contributor.authorSaba, Rabin
dc.contributor.authorGozel, Mustafa Gokhan
dc.contributor.authorTurhan, Ozge
dc.contributor.authorInan, Dilara
dc.contributor.authorAsik, Zahide
dc.contributor.authorKose, Adem
dc.date.accessioned2024-08-04T20:43:56Z
dc.date.available2024-08-04T20:43:56Z
dc.date.issued2017
dc.departmentİnönü Üniversitesien_US
dc.description.abstractIntroduction: This study was initiated to investigate the risk factors of secondary infections in febrile neutropenic patients following chemotherapy, and to evaluate the clinical, microbiological, and mortality outcomes of these infections. Methodology: An evaluation was done on all patients with hematological malignancy who developed a febrile neutropenic episode (FNE) after cytotoxic chemotherapy in the Department of Hematology, Akdeniz University Faculty of Medicine, between January 2007 and December 2008. Results: A total of 294 primary FNEs that responded to the initial empirical or targeted treatment were included in the study, and secondary infections developed after 72 (24.5%) of 294 primary FNEs. Risk factors for secondary infections were determined as acute leukemia as the underlying disease, salvage chemotherapy for refractory/relapse diseases, prolonged neutropenia (10 days and over), Multinational Association of Supportive Care in Cancer (MASSC) score < 21, and fungal infection during the primary episode. The mortality rate of patients who developed secondary infections was significantly higher compared to patients without secondary infections (27.8% and 5.4%, respectively; p = 0.001). Conclusions: The development of secondary infections in patients with hematological malignancy was not very rare. Greater concern should be shown for these infections to increase patient survival rates.en_US
dc.identifier.doi10.3855/jidc.8530
dc.identifier.endpage526en_US
dc.identifier.issn1972-2680
dc.identifier.issue7en_US
dc.identifier.pmid31071060en_US
dc.identifier.scopus2-s2.0-85026840406en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage521en_US
dc.identifier.urihttps://doi.org/10.3855/jidc.8530
dc.identifier.urihttps://hdl.handle.net/11616/97919
dc.identifier.volume11en_US
dc.identifier.wosWOS:000410959000001en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherJ Infection Developing Countriesen_US
dc.relation.ispartofJournal of Infection in Developing Countriesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjecthematological malignancyen_US
dc.subjectcytotoxic chemotherapyen_US
dc.subjectfebrile neutropeniaen_US
dc.subjectsecondary infectionen_US
dc.titleSecondary infections after cytotoxic chemotherapy in patient with hematological malignanciesen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu